**STANDFIRST**

Following administration of antiretroviral therapy in advanced AIDS, a preponderance of the increased CD4 T cells in blood are Th~2~-biased, tissue-derived T cells, resulting in a strong imbalance of functional subsets compared to healthy adults.

INTRODUCTION
============

Highly active antiretroviral therapy (ART) for the treatment of HIV-1 effectively suppresses plasma viral load (PVL) in a vast majority of individuals, as well as gradually restoring CD4^+^ T-cell numbers and function. The reconstitution of the CD4^+^ T-cell compartment in peripheral blood is essentially biphasic \[[@B1][@B2]--[@B3]\]. An early, rapid increase during the first three weeks \[[@B3], [@B4]\] may be due to redistribution of memory cells to the peripheral blood from sites of inflammation in the tissues; subsequently, a slower phase, evident after about three months of treatment, is at least in part due to *de novo* production of naïve CD4^+^ T cells from the thymus \[[@B3], [@B5]\], as well as improved T-cell survival \[[@B6], [@B7]\]. The frequency of proliferating (Ki67^+^) cells decreases in both the CD4^+^ and CD8^+^ T-cell compartments, with a transient increase after 6 months of therapy, mainly in CD4^+^ central memory (T~CM~) cells \[[@B8]\]. More advanced patients are reported to have proportionately faster reconstitution rates \[[@B9]\], though the lower the CD4^+^ T-cell nadir, the longer it takes to normalize this population \[[@B10]\]. More advanced patients are reported to have proportionately faster reconstitution rates, though the lower the CD4^+^ T-cell nadir, the longer it takes to normalize this population.

Beyond these basic changes, less is known about the evolution of the T-cell compartment\'s composition during ART. The most profound change described within the CD4^+^ and CD8^+^ T-cell lineages is an overall reduction in activation, as evidenced by loss of cells expressing CD38 \[[@B1], [@B9], [@B11]\] and HLA-DR \[[@B1], [@B11], [@B12]\], and a decrease in the mean fluorescence intensity (MFI) of CD38 on CD8^+^ T-cells \[[@B11], [@B13], [@B14]\]. These changes represent a (partial) normalization of the T-cells\' pheno-type, towards that seen in healthy adults.

The HIV-specific T-cell response also changes dramatically following ART. Independent of the epitope, HIV-specific CD8^+^ T-cell responses exhibit an early, rapid decline, continued with slower kinetics once plasma viral loads have been suppressed to undetectable levels \[[@B15]\]. This reduction in magnitude is not accompanied by a change in the quality of the CD8^+^ T-cell response \[[@B16]\]; however, like the bulk T-cell compartment, the expression of CD38 and HLA-DR on HIV-1 Gag-specific T cells decreases during treatment \[[@B11]\].

Despite these apparent normalizations, treated subjects still have immune defects. Therefore, we set out to determine T-cell dynamics during ART in total, as well as in HIV-1 Gag-specific CD4^+^ and CD8^+^ T cells. We found an overall rebalancing in the differentiation of T cells, favoring less differentiated cells; in addition, molecules related to activation and functional suppression gradually decreased during treatment, trending towards levels observed in healthy individuals. In sharp contrast to these expected findings, the proportion of Th~2~-like CD4^+^ T~CM~ increased for at least six months following ART initiation, in a direction away from frequencies typical for healthy adults; these cells have characteristics of mucosal-derived cells. Therefore, ART-induced immune reconstitution does not necessarily lead to a normalization of the immune system as a whole, and may, for at least a year, lead to a state that is Th~2~-biased in nature.

MATERIALS AND METHODS
=====================

### Ethics statement.

HIV-1^+^ subjects were enrolled and provided written informed consent at the Clinical Center of the National Institute of Allergy and Infectious Diseases, NIH, under a protocol approved by the NIAID Institutional Review Board. These studies were registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) as \#NCT00557570 and \#NCT00286767. Samples were coded; all analyses were performed blinded to identity.

### Human subjects and sample collection.

The patient cohort has been described elsewhere \[[@B17]\]. Briefly, all patients (1) were ART-naïve (n = 56) or had interrupted treatment for at least one year (n = 4, plus n = 2 who had previously received brief mono- or dual therapy) with a viral rebound of \> 10,000 copies/ml; (2) had ≤ 200 CD4^+^ T cells/μl at baseline; (3) suppressed their HIV-1 viral load to \<500 copies/ml within one year of ART; and (4) had available peripheral blood mono-nuclear cell (PBMC) samples taken pre-ART as well as after 1, 3, 6, and 12 months of ART. Seventeen patients developed episodes of immune reconstitution inflammatory syndrome (IRIS; defined according to the AIDS Clinical Trials Group criteria, \<<https://actgnetwork.org/IRIS_Case_Definitions>\>) following commencement of ART, while 39 underwent uneventful immune reconstitution. PBMC from 12 healthy donors served as controls ([Table 1](#T1){ref-type="table"}).

###### 

PATIENT COHORT CHARACTERISTICS

                                                                            HIV^+^             HIV^−^
  ------------------------------------------------------------------------- ------------------ ------------------
  *n*                                                                       56                 12
  age ^[A](#TF1-1){ref-type="table-fn"},[B](#TF1-2){ref-type="table-fn"}^   37.2 (31.2-43.2)   36.4 (32.5-39.3)
  male (%)                                                                  76.8               66.7
  ethnicity (%)                                                                                
  African                                                                   51.8               58.3
  Asian                                                                     0.0                8.3
  Caucasian                                                                 14.3               16.7
  Hispanic or Latino                                                        25.0               0.0
  Native American or Alaska Native                                          1.8                0.0
  mixed                                                                     7.1                16.7
  ART component (%)                                                                            
  NNRTI ^[C](#TF1-3){ref-type="table-fn"}^                                  64.3               
  PI ^[C](#TF1-3){ref-type="table-fn"}^                                     35.7               
  Time relative to ART initiation (months)                                                     
  pre-ART                                                                   -0.2 (-0.5-0)      
  mo1                                                                       1 (0.9-1.2)        
  mo3                                                                       3 (2.8-3.2)        
  mo6                                                                       5.6 (5.6-6.1)      
  mo12                                                                      12 (11.2-12.5)     

HIV^+^: at ART initiation; HIV^−^: at time of PBMC sampling

Median (IQR)

NNRTI: non-nucleoside reverse-transcriptase inhibitors; PI: protease inhibitors

For the elucidation of T-helper subsets ([Figures 5](#F5){ref-type="fig"}--[6](#F6){ref-type="fig"}), PBMC of an additional 13 HIV-1^+^ individuals were sampled before, as well as one month, and 12 months after initiation of ART. Their clinical parameters were comparable to that of the main cohort, with the following medians and inter-quartile ranges pre-ART: 56 (20-77) CD4^+^ T cells/μl, 572 (469-744) CD8^+^ T cells/μl, 4.8 (4.5-5.4) log~10~ PVL; after 1 month of ART: 129 (101-152) CD4^+^ T cells/μl, 918 (589-1105) CD8^+^ T cells/μl, 2.3 (1.9-2.7) log~10~ PVL; and after 12 month of ART: 210 (199.8-264.5) CD4^+^ T cells/μl, 795.5 (555.5-950) CD8^+^ T cells/μl, 1.7 (1.7-1.7) log~10~ PVL. None of these patients experienced IRIS. PBMC from an additional 16 healthy donors served as controls for this part of the study.

### Determination of plasma viral load, CD4^+^, and CD8^+^ cell counts.

Plasma HIV-1 viral loads (PVL), as well as CD4 and CD8 counts were determined in a laboratory operating under the Clinical Laboratory Improvement Amendment (CLIA). The plasma viral load was measured using the ultrasensitive Quantiplex HIV-1 bDNA version 3.0 (Bayer). CD4^+^ and CD8^+^ T-cell counts were determined by four-color flow cytometry. The BD Multitest (BD Biosciences) that was used includes the following Abs: CD3^FITC^ (clone SK7); CD4^APC^ (clone SK3); CD8^PE^ (clone SK1); and CD45^PerCP^ (clone 2D1). Samples were acquired on either FACSCalibur or FACSCanto (both BD Biosciences). CD4^+^ cell counts were calculated as percent of CD4^+^ CD3^+^ cells within CD45^+^ lymphocytes divided by 1% of the white blood cell count. The corresponding calculation was performed for CD8^+^ cell counts.

### Sample preparation and Ag-stimulation.

Cryopreserved PBMC were thawed in pre-warmed RPMI 1640, 10% FCS, 2mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Gibco; this medium will hereafter be referred to as complete RPMI), in the presence of 20 μg/ml benzonase nuclease (Novagen). Cells were rested in complete RPMI for 4-6 hours at 37°C, 5% CO~2~ and either left unstimulated (mock control) or stimulated overnight in 200 μl complete RPMI with 2.5 μg/ml HIV-1 Gag peptide pool (NIH AIDS Research and Reference Reagent Program, Germantown MD) in the presence of anti-CD49d and anti-CD28^PE\ -Cy5^ mAb (BD Biosciences). Monensin and Brefeldin A (BD Biosciences) were added after 2 hours of stimulation. Healthy donor PBMC were stimulated with SEB (Sigma) to serve as a positive control.

### Flow cytometry.

The reagent panels used in the present study are listed in [Supplementary Table 1](#TS1){ref-type="table"}. All except the "Th subset" and "sorting" panels have been described in previous publications \[[@B17], [@B18]\]. The "Th subset" panel included the following additional reagents: CCR6^Ax488^ (clone TG7/ CCR6); CCR10^PE^ (clone 6588-5, both from BioLegend); CXCR3^PE-Cy5^ (clone 1C6/CXCR3); and HLA-DR^PE-Cy5.5^ (clone TÜ36, both from BD Biosciences). The "sorting" panel included the following additional reagents: CCR6^BV605^ (clone G034E3); CCR4^PE-Cy7^ (clone TG6/CCR4, both from BioLegend); CD4^APC^ (clone RPA-T4, BD Biosciences); as well as TCR-Vβ12 (clone VER2.32.1); TCR-Vβ14 (clone CAS1.1.1.3); and TCR-Vβ17 (clone E17.5F3.15.13) conjugated to FITC (Life Technologies) at the VRC; and TCR-Vβ1 (clone BL37.2); TCR-Vβ2 (clone MPD2D5); TCRVβ7 (clone ZOE); TCR-Vβ13.6 (clone JU74.3); TCR-Vβ16 (clone TAMAYA1.2); and TCR-Vβ22 (clone IMMU546) conjugated to Ax594 (Life Technologies) at the VRC. All unconjugated TCRVβ Abs were obtained from Beckman Coulter. For intracellular staining, cells were treated with BD Cytofix/Cytoperm Permeabilization Solution (BD Biosciences), except for the T~reg~ panel, where the Foxp3 Staining Buffer Set was employed (eBioscience). Data were acquired on an LSR II (BD Biosciences) using a high-throughput system (HTS).

### Multi-parametric quantitative RT-PCR.

We largely followed the protocols set forth by Dominguez *et al*. \[[@B19]\]. Briefly, TaqMan^TM^ primer/probe sets (Life Technologies) were chosen for genes relevant for T-cell immunity, including those associated with cytokines, cytokine receptors, migration, proliferation, chemokines, cytolysis, transcription factors, activation, and costimulation (see [Supplementary Table 2](#TS2){ref-type="table"}). Depending on subset abundance, 10-100 cells were sorted by fluorescence-activated cell sorting for assessment of gene expression in different CD4^+^ T-cell subsets ([Supplementary Figure 5](#FS5){ref-type="fig"}). Cells were sorted directly into cell culture plates containing 10μl of reaction mix (Invitrogen Cell Direct Kit^TM^, Life Technologies); the manufacturer\'s instructions were followed for reverse transcription (15min at 50°C) and cDNA synthesis (2min at 95°C; 15sec at 95°C; 4min at 60°C). Seventeen pre-amplification cycles were performed (15sec at 95°C; 4min 60°C).

Pre-amplified cDNA, and TaqMan^TM^ primer/probes were loaded onto a microfluidic chip (Fluidigm), and multi-parametric quantitative RT-PCR was performed using a Biomark^TM^ cycler (Fluidigm) as previously described \[[@B19]\].

### Data analysis.

Flow cytometry data were analyzed using FlowJo (FlowJo, LLC), Pestle (NIAID, NIH; by M. Roederer), and SPICE 5.1 \[[@B20]\]. The gating scheme is identical to that used in our previous publications \[[@B17], [@B18]\]. All cytokine measurements were background subtracted, taking into account the frequency of cells producing cytokines in the absence of antigenic stimulation (mock control). For the phenotypic analysis of Ag-specific cells, only those samples with \>10 cytokine-positive events and response magnitudes \> 3x that of the corresponding mock control were considered. The mean fluorescence intensity (MFI) of CD38^+^ cells was calibrated using the experiment-matched internal control sample.

RT-PCR data were analyzed using JMP 11 (SAS), R 3.1, and Bioconductor \[[@B21]\]. Because varying cell numbers were sorted for RT-PCR of individual T-cell subsets, all samples were normalized to 50 cells. Relative gene expression levels or "expression threshold" (Et) are proportional to log~2~ RNA abundance and were calculated using the "cycle threshold" (Ct) obtained, where Et = 28-Ct \[[@B19]\]. The following genes, expressed by less than 10% of samples analyzed, were excluded from the analysis, as this could due to inefficient amplification: CXCL11; CXCR1; CXCR2; GPR44; IL5; IL9; and TGFB2.

### "Th-ness" and Differentiation Index (DI).

Th-ness was defined as the posterior probability \[[@B22], [@B23]\] of class membership given by a support vector machine (SVM) \[[@B24], [@B25]\] trained to differentiate between all sorted healthy donor Th~1~- and Th~2~-like cells with radial basis kernel. All sorted CCR4^+^ T~CM~, CCR4^+^ non-T~CM~, CCR4^−^ T~CM~, and CCR4^−^ non-T~CM~ samples were then assigned a Th-ness value according to their gene expression pattern, indicating whether their phenotype was more similar to Th~1~- or Th~2~-like cells. Accuracy of the SVM was 90% for three-fold cross validation.

Each T-cell subset was assigned a weighting value as follows: T~NV~ = 0; T~CM\*~ = 1; T~CM~ = 2; T~TM\*~ = 3; T~TM~ = 4; T~EM~ = 5; T~TE\*~ = 6; T~TE~ = 7. The DI is the average of the subset frequencies weighted by their respective values. As Nv cells do not contribute to a population\'s overall differentiation, they are assigned a weighting of 0. The weighted sum is then normalized by the maximum differentiation value (7) to derive a metric ranging from 0 to 1: DI = ((%T~NV~ \* 0) + (%T~CM\*~ \* 1) + (%T~CM~ \* 2) + (%T~TM\*~ \* 3) + (%T~TM~ \* 4) + (%T~EM~ \* 5) + (%T~TE\*~ \* 6) + (%T~TE~ \* 7)) / 7 / 100%.

### Statistical analysis.

Nonparametric tests were used for all analyses (SAS version 9.2); matched comparisons were performed where applicable. Changes from baseline (paired differences) were evaluated using the Sign test. Statistical comparisons of pie charts were performed in SPICE 5.1 software using 10,000 permutations \[[@B20]\]. Given the exploratory nature of this study, there was no adjustment for multiple comparisons; in most analyses, only *P*-values less than 0.01 are reported.

Differential expression analysis of genes assayed by RT-PCR was performed using Limma \[[@B26][@B27]--[@B28]\]. Results for CD103 were obtained via robust regression \[[@B29], [@B30]\]. All *P*-values from differential expression analyses were then pooled for control of false discovery rate \[[@B31]\]. Significance was then defined as an adjusted *P*-value less than 0.01.

RESULTS
=======

Overall ART-Responsiveness
--------------------------

Fifty-six HIV-1^+^ patients commenced ART when their CD4^+^ T-cell count was ≤ 200/μl. Phenotype and HIV-1 Gag reactivity of their PBMC-derived T cells were characterized before ART, as well as at 1, 3, 6, and 12 months after ART-initiation ([Table 1](#T1){ref-type="table"}). All patients rapidly responded to ART, evidenced by a 3-log suppression of the PVL within a month and to undetectable levels within 3 months ([Supplementary Figure 1](#FS1){ref-type="fig"}A). The CD4^+^ T-cell counts gradually increased during the time of follow-up. Though the increase was significant within 1 month of treatment, T-cell counts still remained largely below those observed in healthy adults at 1 year ([Supplementary Figure 1](#FS1){ref-type="fig"}B). CD8^+^ T-cell counts, which started in the range of levels typically observed in healthy adults, increased only during the first month of treatment ([Supplementary Figure 1](#FS1){ref-type="fig"}C) \[[@B18]\].

Longitudinal Analysis of HIV-Specific T-Cell Responses During ART
-----------------------------------------------------------------

Even though the magnitude of the HIV-specific CD4^+^ T-cell response did not change within the first year of ART ([Figure 1](#F1){ref-type="fig"}A), these cells became more polyfunctional (*i.e.*, producing two or three cytokines) over time, achieving statistical significance at late sampling time-points (6-12 months of ART, [Figure 1](#F1){ref-type="fig"}B). This change in cytokine pattern was mainly due to increased IL-2 production ([Figures 1](#F1){ref-type="fig"}B, C). The subset distribution within HIV-responsive CD4^+^ T cells was also affected by ART: as early as 3 months after commencing ART, less differentiated cells (T~CM~, T~TM~) increased, with a concomitant reduction in T~EM~ cells ([Figure 1](#F1){ref-type="fig"}D). However, no significant change in the differentiation index (DI; see supplementary methods section) of HIV-1 Gag-specific CD4^+^ T cells was observed. Furthermore, the ART-induced reversal of other differentiation and inhibitory receptors\' expression was much less dramatic for HIV-specific cells ([Figure 1](#F1){ref-type="fig"}E) than that for total CD4^+^ T cells (see below). Though there were trends mirroring total CD4^+^ T cells, no statistically significant changes were observed in the phenotype of HIV-specific CD4^+^ T cells. Taken together, these data indicate that while the overall magnitude of HIV-specific CD4^+^ T cells remained unaffected by ART, these cells became mildly more enriched for less differentiated cells without changes in activation state.

![Longitudinal analysis of HIV-1 Gag-specific cytokine production by T cells and the phenotype of cytokine-producing cells. The effect of ART on HIV-1 Gag-reactive CD4^+^ (A-E) and CD8^+^ T cells (F-J) was determined in longitudinal PBMC samples of HIV-1^+^ patients. (A, F) Total response magnitude, measured by production of IFN-γ, IL-2, or TNF. (B, G) Cytokine pattern. Relative proportion of total HIV-1 Gag-reactive cells producing each possible combination of the cytokines measured. Black arcs indicate all IL-2 (B) or IFN-γ (G) producing cells. (C, H) Actual frequency of cells producing only IFN-γ, IL-2, or TNF, or any combination thereof. Potential phenotypic alterations occurring due to ART were explored in HIV-1 Gag-reactive CD4^+^ (D, E) and CD8^+^ T cells (I, J) in longitudinal PBMC samples of HIV-1^+^ patients. (D, I) Differentiation state. T-cell differentiation subsets of cytokine-positive cells were defined by expression of CD45RO ("RO"), CCR7 ("R7"), and CD27 ("27"). Differentiation indices (DI; medians and interquartile ranges) are indicated below each pie. (E, J) Phenotype. The frequency of cytokine-positive cells expressing differentiation markers (CD7, CD28, CD31, CD57, CD127) or inhibitory receptors (PD-1, TIM-3) was determined. Graphs show interquartile ranges, median bars, as well as individual data points. All time-points were compared to corresponding pre-ART measurements: \**P* \<0 .01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.](pai-1-260-g001){#F1}

In contrast, HIV-specific CD8^+^ T cells reacted very differently to ART than their CD4^+^ counterparts. As previously published \[[@B11], [@B16]\], there was a significant decrease in the magnitude of the CD8^+^ T-cell response to HIV-1 ([Figure 1](#F1){ref-type="fig"}F). However, the cytokine pattern remained virtually unchanged for at least one year of treatment ([Figures 1](#F1){ref-type="fig"}G, H). The subset distribution of HIV-responsive CD8^+^ T cells remained unchanged ([Figure 1](#F1){ref-type="fig"}I), and their DI did not change significantly over the course of study. The ART-induced reversal of other differentiation and inhibitory receptors\' expression was also less dramatic ([Figure 1](#F1){ref-type="fig"}J) than that observed in total CD8^+^ T cells ([Supplementary Figure 2](#FS2){ref-type="fig"}).

Longitudinal Analysis of CD4^+^ and CD8^+^ T-Cell Differentiation During ART
----------------------------------------------------------------------------

We examined the evolution of T-cell differentiation over the course of ART; differentiation stage was defined by classifying cells (in rough order of maturation) as naïve (T~NV~), central memory (T~CM~ and T~CM\*~), transitional memory (T~TM\*~ and T~TM~), effector memory (T~EM~), or terminal effector (T~TE\*~ and T~TE~) \[[@B32]\]. There were significant changes in the CD4^+^ T-cell subset distribution after starting ART ([Figure 2](#F2){ref-type="fig"}A), with increasing proportions of less differentiated subsets (T~NV~, T~CM~, T~TM\*~) over the course of treatment and a concomitant reduction in the proportion of highly differentiated cells (T~TE~). As previously reported, the frequency of T~CM~ was increased at mo1 ([Figure 2](#F2){ref-type="fig"}B), prior to that of T~NV~, which became significant only at 1 year ([Figure 2](#F2){ref-type="fig"}D). This is a reflection of the initial redistribution of memory cells \[[@B4]\] followed by a delayed *de novo* production and improved survival of cells \[[@B3], [@B5][@B6]--[@B7]\]. While the relative frequency of T~NV~ initially decreased due to the preferential release of memory cells from secondary lymphoid tissues, their absolute numbers increased upon introduction of ART ([Figure 2](#F2){ref-type="fig"}E), together with that of T~CM~ ([Figure 2](#F2){ref-type="fig"}C). The proportion of CD4^+^ T cells in late differentiation stages (T~EM~, T~TE\*~, and T~TE~) steadily decreased after ART initiation ([Figure 2](#F2){ref-type="fig"}F). Consequently, the DI of the total CD4^+^ T-cell compartment progressively decreased over the course of ART ([Figure 2](#F2){ref-type="fig"}A). Interestingly, patients with higher pre-ART levels of late differentiation (T~EM−TE~) CD4^+^ T cells demonstrated lower pre-ART PVL ([Figure 2](#F2){ref-type="fig"}G), but also a less dramatic recovery of CD8^+^ T-cell counts.

![ART-induced change towards less differentiated CD4^+^ T cells. PBMC were sampled before ART, and after 1, 3, 6, and 12 months of ART. (A) The differentiation pattern was investigated in CD4^+^ T cells. Subsets were defined by expression of CD45RO ("RO"), CCR7 ("R7") and CD27 ("27"). T~NV~--naïve; T~CM~--central memory; T~TM~--transitional memory; T~EM~--effector memory; T~TE~--terminal effector. T~CM\*~, T~TM\*~, and T~TE\*~ are populations not classically discussed in the literature, but arise by this gating scheme; their activation phenotype and cytokine potential most closely resemble that of T~CM~, T~TM~, and T~TE~, respectively, hence their nomenclature. Differentiation indices (DI; medians and interquartile ranges) are indicated. The change in frequency over the course of treatment relative to pre-ART levels (B, D), as well as absolute cell count (C, E) of T~NV~ (B, C) and T~CM~ (D, E), and total frequency of late-differentiation (T~EM~, T~TE\*~, and T~TE~) (F) CD4^+^ T-cells are shown. (G) Pre-ART PVL was plotted against pre-ART late-differentiation (T~EM~, T~TE\*~, and T~TE~) CD4^+^ T cells. Graphs show development in individual patients, as well as medians and interquar-tile ranges. Corresponding interquartile ranges in healthy donors are shown where applicable (orange). All time-points were compared to corresponding pre-ART measurements: \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.](pai-1-260-g002){#F2}

Nineteen of the 56 patients developed Immune Reconstitution Inflammatory Syndrome (IRIS) following ART initiation, which we showed alters CD4^+^ T-cell reconstitution kinetics, mainly by delaying T~NV~ recovery and the concomitant reduction of T~EM~, which are most evident at mo6 \[[@B18]\]. As a result, the inclusion of patients experiencing IRIS after commencing ART delayed the overall observed decrease of T~EM−TE~ CD4^+^ T cells (mo3 *vs.* pre-ART: *P* = .0465 IRIS, *P* = .0005 non-IRIS).

Changes in CD8^+^ T-cell subset distribution, though similar to those observed in CD4^+^ T cells, were much more subtle and only became statistically significant after many months of treatment, though some individual subsets exhibited significant changes early on (T~CM\*~, T~CM~; [Supplementary Figure 2](#FS2){ref-type="fig"}A, B).

Expression of Differentiation, Activation and Inhibitory Markers
----------------------------------------------------------------

Alterations in T-cell activation phenotypes that might occur as a result of ART were comprehensively evaluated using a large range of cellular markers of T-cell differentiation, activation, and negative regulation. An ART-induced normalization of CD4^+^ T-cell differentiation was evidenced by a gradual increase in the frequency of cells expressing CD28 and CD127, paralleled by a down-regulation of the senescence marker CD57, as well as an increase in CD31^+^ cells and recent thymic emigrants (CD31^+^ CD45RO^−^ CCR7^+^) after 1 year of therapy ([Figure 3](#F3){ref-type="fig"}(a)). A concomitant decrease in CD4^+^ T-cell activation was indicated by decreasing frequencies of CCR5^+^, CD38^+^, GrB^+^, and Ki67^+^ cells ([Figure 3](#F3){ref-type="fig"}(b)). There was also a decrease in the MFI of CD38 expression ([Figure 3](#F3){ref-type="fig"}(c)); elevated expression of CD38 has been closely linked to poor prognosis in HIV-1 infection \[[@B33]\]. The proportion of CD4^+^ T cells expressing the inhibitory receptors CTLA-4, LAG-3, or TIM-3 also declined during this time ([Figure 3](#F3){ref-type="fig"}(d)). Compared to healthy adults, markers of CD4^+^ T-cell differentiation, activation, and expression of negative regulators normalized (or trended in that direction) over 1 year of ART.

![Reversal of CD4^+^ and T-cell activation during ART. Phenotypic characteristics of CD4^+^ T cells were analyzed by polychromatic flow cytometry in PBMC sampled before ART, as well as after 1, 3, 6, and 12 months of ART. (A) T-cell differentiation and subtypes; RTE--recent thymic emigrants. (B) Markers of activation; GrB--Granzyme B. (C) Mean fluorescence intensity of CD38. (D) Inhibitory receptors. Graphs show interquartile ranges, median bars, as well as individual data points. Orange areas represent the inter-quartile ranges of corresponding measurements in healthy individuals. All time-points were compared to corresponding pre-ART measurements: \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001. i.d.--insufficient data.](pai-1-260-g003){#F3}

In contrast, the frequency of cells expressing CCR4 ([Figure 3](#F3){ref-type="fig"}A), HLA-DR, ICOS ([Figure 3](#F3){ref-type="fig"}B), and PD-1 ([Figure 3](#F3){ref-type="fig"}D) increased to levels significantly more disparate from those observed in healthy adults. This trend was transient for HLA-DR, ICOS, and PD-1, while for CCR4 it continued for at least one year. Note that the CCR4-expressing cells must be predominantly against specificities other than HIV, as their numbers are substantially greater than HIV-specific CD4 T cells ([Figure 1](#F1){ref-type="fig"}).

CD8^+^ T-cell differentiation and activation normalized during treatment, but much less dramatically than that of CD4^+^ T cells, as indicated by increased CCR4, CD28, and CD127 and decreased CD57 ([Supplementary Figure 2](#FS2){ref-type="fig"}C). The inhibitory receptors CTLA-4, LAG-3, PD-1, and TIM-3, the activation markers CCR5, CD38, FoxP3, GrB, HLA-DR, ICOS, and Ki67, as well as the MFI of CD38, all declined towards normal levels ([Supplementary Figure 2](#FS2){ref-type="fig"}D-F). Interestingly, while the phenotype of CD4^+^ T cells appeared to become more similar between patients over time (reduced range of activation marker expression), this was not the case for CD8^+^ T cells.

Co-Expression of CCR4, HLA-DR, ICOS, and PD-1
---------------------------------------------

In contrast to all the other measured parameters, the expression of CCR4, HLA-DR, ICOS, and PD-1 on CD4^+^ T cells increased upon ART initiation, becoming more disparate from levels observed in healthy donors. Thus, we investigated co-expression of these molecules pre-ART and at mo1 of ART in HIV-1^+^ individuals, as well as in healthy donors. Even in healthy individuals, a large proportion of HLA-DR^+^, ICOS^+^, and PD-1^+^ CD4^+^ T cells expressed CCR4. In HIV-1^+^ patients, the CCR4^+^ fraction of ICOS^+^ and PD-1^+^ cells significantly increased shortly after commencing ART ([Figure 4](#F4){ref-type="fig"}A). In contrast, even though the frequency of activated CCR4^+^ CD4^+^ T cells was more elevated in HIV-1^+^ patients compared to healthy donors, as measured by the expression of HLA-DR, ICOS, and PD-1, the introduction of ART did not significantly alter the proportion of activated cells ([Figure 4](#F4){ref-type="fig"}B) or the co-expression pattern of these three activation markers (unpublished data). Taken together, these results show that the increase of HLA-DR^+^, ICOS^+^, and PD-1^+^ CD4^+^ T cells is due to the increase in activated CCR4^+^ cells.

![Early appearance of activated CCR4^+^ T~CM~ in peripheral blood during ART. PBMC samples taken pre-ART and after one month of ART (mo1) were analyzed to investigate co-expression of CCR4, HLA DR, ICOS, and PD-1 on CD4^+^ T cells, as well as whether these phenotypes coincide with the T~CM~ subset. (A) Frequency of CCR4^+^ cells within HLA-DR^+^, ICOS^+^, and PD-1^+^ cells. (B) Frequency of HLA-DR, ICOS, or PD-1 expressing CCR4^+^ cells. Expression of Th subset-defining chemokine receptors on CCR4^+^ (C) or non-naïve (D) CD4^+^ T cells. (E) Differentiation pattern of CCR4^+^ cells. Differentiation indices (DI; medians and interquartile ranges) are indicated below each pie. (F) Expression of Th subset-defining chemokine receptors on T~CM~ cells. (G) Proportion of CCR4^+^ T~CM~ and CCR4^−^ T~CM~ over time. (H) Expression of the proliferation marker Ki67 in CCR4^+^ T~CM~ and CCR4^−^ T~CM~ over time. Bar graphs show interquartile ranges, median bars, as well as individual data points. The interquartile range of given phenotypes (orange areas in bar charts) or average distribution patterns (pie charts) in healthy donors are shown. Mo1 measurements were compared to corresponding pre-ART values: \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.](pai-1-260-g004){#F4}

Th Subsets
----------

Though the Th~1~/Th~2~ dichotomy, and wider Th-subsetting, of CD4^+^ T cells is less applicable in humans than in mice where it was first described, this system allows the identification of cellular subsets that are associated with specific functions. Hence, we here make use of the phenotypically and functionally described Th-subsets, referring to them as "Th~X~-like" where possible.

The increased prevalence of CCR4 on CD4^+^ T cells after ART initiation led us to investigate the relative representation of functionally distinct T-helper subsets prior to and during ART, as CCR4 is preferentially expressed on Th~2~-like cells. To this end, the expression pattern of CCR4, CCR6, CCR10, and CXCR3 was analyzed in order to identify cells reminiscent of Th~1~ (CCR4^−^, CCR6^−^, CXCR3^+^)\[[@B34][@B35]--[@B36]\], Th~2~ (CCR4^+^, CCR6^−^, CXCR3^−^) \[[@B36], [@B37]\], Th~17~ (CCR4^+^, CCR6^+^, CXCR3^−^) \[[@B38]\], as well as Th~1~Th~17~ cells (CCR4^−^, CCR6^+^, CXCR3^+^) capable of producing both IFN-γ and IL-17 \[[@B38]\] ([Supplementary Figure 3](#FS3){ref-type="fig"}). Th~9~- (CCR4^−^, CCR6^+^, CXCR3^−^) and Th~22~-like cells (CCR4^+^, CCR6^+^, CCR10^+^) \[[@B39]\] can also be defined using the present chemokine receptors, but these populations were too infrequent to be robustly quantifiable.

In accordance with CCR4 being preferentially expressed on Th~2~-like cells \[[@B40]\], the majority of CCR4^+^ CD4^+^ T cells did not express any of the other chemokine receptors analyzed. In HIV-1^+^ patients, most CCR4^+^ cells were thus defined as Th~2~-like cells, and their composition was not affected by ART ([Figure 4](#F4){ref-type="fig"}C). However, the fraction of non-naïve CD4^+^ T cells expressing a Th~2-~like phenotype increased significantly after the induction of ART, while the proportion of Th~1~-like cells was relatively low in HIV-1^+^ patients at both time-points ([Figure 4](#F4){ref-type="fig"}D).

Th~2~-Like Cells and the T~CM~ Phenotype
----------------------------------------

Because a hallmark of ART-induced immune reconstitution is the early rise in the number and frequency of CD4^+^ T~CM~ \[[@B41]\], we investigated how the Th subsets, in particular Th~2~-like cells, correlated with this phenotype. As seen with total CD4^+^ T cells, the differentiation pattern of CCR4^+^ CD4^+^ T cells was biased towards a more differentiated population in HIV-1+ individuals. After 1 month of ART, this pattern, as well as the DI, remained unchanged, with T~CM~ representing close to 50% of CCR4^+^ cells ([Figure 4](#F4){ref-type="fig"}E). While in healthy individuals CD4^+^ T~CM~ cells harbored balanced proportions of Th1-, Th~2~-, Th~17~-, and Th~1~Th~17~-like cells, in HIV-1^+^ patients this population was biased towards a Th~2~-like phenotype. Unlike most other changes we observed within the CD4^+^ T-cell compartment, this altered representation was dramatically exacerbated by ART initiation ([Figure 4](#F4){ref-type="fig"}F). The co-expression pattern of HLA-DR, ICOS, and PD-1 on CD4^+^ T~CM~ closely mimicked that of CD4^+^ CCR4^+^ cells and was not affected by ART. This indicates that the observed early increases of CD4^+^ CCR4^+^ T cells and CD4^+^ T~CM~ largely identify the same population. Indeed, CCR4^+^ T~CM~ increased in frequency upon ART initiation, while CCR4−T~CM~ did not ([Figure 4](#F4){ref-type="fig"}G). Notably, proliferation, as measured by the expression of Ki67, did not appear to be the primary mechanism for this perceived expansion ([Figure 4](#F4){ref-type="fig"}H).

CCR4^+^ T~CM~ are Not Genotypically Identical to Th~2~-Like Cells
-----------------------------------------------------------------

To investigate whether CCR4^+^ T~CM~ are *bona fide* Th~2~-like cells, we compared the transcriptional profile of CCR4^+^ T~CM~, Th~2~- and Th~1~-like SEB-reactive CD4^+^ T cells from healthy donors. CCR4^+^ T~CM~ indeed closely resembled Th~2~-like cells in respect to the expression of Th~2~- ([Figure 5](#F5){ref-type="fig"}A) and Th~1~-associated genes ([Supplementary Figure 5](#FS5){ref-type="fig"}), as well as most of the other cytokine genes investigated ([Figure 5](#F5){ref-type="fig"}B). The only genes differentially expressed in these two cellular populations were IL21 and IL22 (both positive in CCR4^+^ T~CM~), the latter of which is typically produced by Th~17~- and Th~22~-like cells \[[@B42], [@B43]\]. CCR4^+^ T~CM~ are unlikely to be Th~22~-like, however, as their levels of IL4 and IFNg transcripts are similar to those of Th~2~- and Th~1~-like cells, respectively, neither of which is produced by Th~22~ \[[@B44]\]. Unlike Th~2~- or Th~1~-like cells, CCR4^+^ T~CM~ demonstrated some IL17a expression. This, together with expression of IL21 and IL22, suggests that these cells might contain an important fraction of cells with Th~17~-like functionality, even though chemokine receptor expression reveals only a small fraction of cells with a Th~17~-like phenotype (CCR4^+^ T~CM~ have a chemokine receptor expression pattern comparable to total CCR4^+^ cells ([Figure 4](#F4){ref-type="fig"}C).

![The gene expression profile of CCR4^+^ T~CM~ is different from that of Th~2~-like cells. PBMC from healthy donors, as well as cells isolated before or after 1 or 12 months of ART from HIV-1-infected adults were stained with the "sorting" panel ([Supplementary Table 1](#TS1){ref-type="table"}). Subsets of CD4^+^ T cells were sorted as indicated in [Supplementary Figure 4](#FS4){ref-type="fig"} and their gene expression profiles determined by multi-parametric quantitative RT-PCR. (A) Th~2~-associated and (B) other cytokine genes were compared in Th~2~-like, CCR4^+^ T~CM~, and Th~1~-like cells isolated from healthy donors. CCR4^+^ T~CM~ from HIV-1^+^ patients after 1 month of ART were compared to their counterparts from healthy donors in respect to expression of (C) Th~2~-associated or (D) other cytokine genes. (E) The expression profile of cytokine genes was investigated in nonnaïve cells. Relative expression in HIV-1-infected individuals before ART, after 1 month of ART, or 1 year of ART was compared to that in healthy donors. (F) The overall gene expression pattern of CCR4^+^ T~CM~, CCR4^+^ T~CM~^−^, CCR4^−^ T~CM~, and CCR4^−^ T~CM~^−^ cells was compared to that of Th~1~- or Th~2~-like cells sorted from healthy donors. Their calculated "Th-ness" is expressed as a point between those two extremes. Bar graphs show interquartile ranges, median bars, as well as individual data points. Statistically significant differences are indicated: \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.](pai-1-260-g005){#F5}

CCR4^+^ T~CM~ cells isolated from HIV-1 infected individuals one month after ART initiation had a transcriptional profile similar to that of healthy donors with respect to Th~2~- ([Figure 5](#F5){ref-type="fig"}C) and Th~1~-associated genes ([Supplementary Figure 5](#FS5){ref-type="fig"}), as well as most other cytokine genes investigated ([Figure 5](#F5){ref-type="fig"}D). However, there was evidence of reduced Th~2~-type cytokine transcript levels, as well as of IL22. This cytokine deficiency was not restricted to CCR4^+^ T~CM~ cells or Th~2~-associated cytokines. We found that total non-naïve cells from ART-naïve HIV-1 patients expressed lower levels of CSF2, IFNg, IL-2, IL-4, IL-10, IL-13, and IL-22 mRNA transcripts ([Figure 5](#F5){ref-type="fig"}E).

When considering all measured genes, CCR4^+^ cell populations (both T~CM~ and non-T~CM~) were mixed in terms of having a more Th~1~- or Th~2~-like gene expression profile, while CCR4^−^ samples were mostly Th~1~-like ([Figure 5](#F5){ref-type="fig"}F).

Emerging CCR4^+^ T~CM~ Upon ART Induction Originate From Peripheral Tissue Sites
--------------------------------------------------------------------------------

Strikingly, in PBMC from HIV-1 infected patients having received ART for one month, the inte-grin αE chain (CD103) was only found to be expressed in CCR4^+^ T~CM~ ([Figure 6](#F6){ref-type="fig"}A). None of the other cell migration markers analyzed were found to differ between these cell populations. This is intriguing, as CD103 is part of the mucosa-homing receptor α~E~β~7~ that is widely expressed on intra-epithelial lymphocytes and lamina propria T cells, as well as on skin-resident T cells. We further investigated this phenomenon by interrogating PBMC samples obtained pre-ART, at mo1 or mo12 of ART, or from healthy donors ([Figure 6](#F6){ref-type="fig"}B). Pre-ART, none of the T-cell subsets investigated showed any CD103 expression, whereas after 1 year of treatment expression was found in both CCR4^+^ T~CM~ and Th~1~-like cells, similar to expression detected in healthy donors. This suggests that, in healthy donors, some CCR4^+^ T~CM~ and Th~1~-like cells recirculate through peripheral tissue sites, while classical Th~2~-like cells do not.

![CCR4^+^ T~CM~ appear to be released from peripheral tissue sites upon ART initiation. PBMC from healthy donors, as well as cells isolated before or after 1 or 12 months of ART from HIV-1-infected adults were stained with the "sorting" panel ([Supplementary Table 1](#TS1){ref-type="table"}). Subsets of CD4+ T cells were sorted as indicated in [Supplementary Figure 4](#FS4){ref-type="fig"} and their gene expression profiles determined by multi-parametric quantitative RT-PCR. (A) CD103 expression on Th~2~-like, CCR4^+^ T~CM~, and Th~1~-like cells isolated after 1 month of antiretroviral therapy. (B) Expression of CD103 in CCR4^+^ T~CM~, Th~2~-, and Th~1~-like cells from healthy donor PBMC (n = 9), and longitudinal samples from HIV-1 patients (n = 12). Bar graphs show interquartile ranges, median bars, as well as individual data points. Statistically significant differences are indicated: \**P* \< 0.01, \*\**P* \< 0.001, \*\*\**P* \< 0.0001.](pai-1-260-g006){#F6}

We investigated the cell surface expression of several migration molecules on CD4^+^ T cells and found varied expression patterns between patients. HIV-1 patients appeared to have somewhat lower levels of CD103^+^ cells than healthy donors, while exhibiting higher levels of CCR9^+^ and integrin b7^+^ cells ([Supplementary Figure 6](#FS6){ref-type="fig"}). This was the case both pre-treatment and after 1 month of ART. Within CD4^+^ T cells, CD103 seemed to be preferentially expressed on CCR4^+^ cells.

There was a discordance in mRNA and protein expression of CD103, which might explain why this aberrantly expanding cellular subset was not identified previously. Down-regulation of CD103 (and other homing markers) typically occurs in a larger fraction of tissue-resident CD4^+^ T~CM~, likely heralding their release into peripheral blood (where we detected them). Maintenance of CD103 mRNA would allow for a rapid re-expression of CD103 proteins and a subsequent return to peripheral tissues.

DISCUSSION
==========

We characterized the phenotypic and functional T-cell dynamics in peripheral blood of severely immuno-compromised HIV-1^+^ individuals following ART. Our data confirm previous findings of an early increase in T~CM~ cells, as well as a gross reduction in overall activation levels. Almost all markers investigated, whether involved in T-cell differentiation, activation, or negative regulation, started normalizing early after ART initiation. These changes were most dramatic in CD4^+^ T cells, but mirrored by similar changes in CD8^+^ T cells, which retained a larger range of individual marker expression than CD4^+^ T cells.

In contrast to the general trend towards normalization, CD4^+^ T-cell activation (HLA-DR, ICOS, PD-1) initially increased in peripheral blood before gradually decreasing, too. CCR4^+^ cells demonstrated a more sustained increase, reflecting a skewing towards a Th~2~-like environment early after ART initiation, and a further deregulation away from the phenotype of healthy donors.

A shift from cells with Th~1~- to those with Th~2~-like functionality has previously been suggested to occur during HIV-1 infection \[[@B45][@B46]--[@B47]\]. It has been reported that long-term non-progressors exhibit a Th~1~-like cytokine profile, while progressors exhibit a Th~2~-like cytokine profile \[[@B47]\], and that increasing viral loads correlate with lower cytoplasmic levels of IL-2 and IFN-γ and concomitant increases in IL-4 and IL-10 levels after stimulation with PMA/ionomycin \[[@B46]\]. Also, certain IL-4Rα SNPs linked to IL-4 hypo-responsiveness may be associated with slower HIV-1 disease progression \[[@B48]\]. The Th~1~- to Th~2~-like switch observed during disease progression was suggested to be at least partially due to an initial selective loss of CCR5^+^ Th~1~-like cells \[[@B49]\]. Our data confirm the presence of an overwhelming predominance of phenotypically Th~2~-like cells during very advanced (\< 200 CD4^+^ T cells/μl) HIV-1 infection.

Early studies have shown that CD4^+^ T~CM~ are released from tissues into the bloodstream early after commencing ART \[[@B4]\], leading to the initial boost in CD4 counts. The present data suggest that these CD4^+^ T~CM~ are primarily CCR4^+^. Thus, the CCR4^+^ T~CM~ cells appearing in the PBMC upon ART do not reflect a phenotypic change of cells preexisting in the blood stream---that is, an ART-induced change in the Th environment---but rather the appearance of a cell type previously sequestered in the tissues \[[@B50], [@B51]\].

This is supported by our findings that, after one month of therapy, CD103 transcripts were specifically expressed by CCR4^+^ T~CM~, while no expression was detected in any of the subsets investigated prior to ART. The α~E~ integrin chain (CD103) is typically found on intra-epithelial lymphocytes, allowing them to home to and circulate through mucosal sites \[[@B52]\]. It represents a rare transcript in peripheral blood CD4^+^ T cells, and indicates that ART induces the release of CCR4^+^ T~CM~ from tissues.

Early after ART commencement, while PVL levels were still in the decline, these CCR4^+^ T~CM~ were highly activated, expressing ICOS, HLA-DR, and PD-1. As the PVL were suppressed to undetectable levels at mo3 of ART, the activation of CCR4^+^ T~CM~ also leveled off. However, there was no normalization of the Th~2~-like phenotype (% CCR4^+^ CD4^+^ T cells), even 1 year after ART.

Gene expression analyses confirmed that the CCR4^+^ T~CM~ cells are largely comparable to classic Th~2~ cells in their Th~1~- and Th~2~-associated transcriptome. However, the fact that CD103 mRNA was detected in CCR4^+^ T~CM~ but not Th~2~-like cells indicated that the cells released from tissues are not classical Th~2~-like cells. Expression of IL21 and IL22 (and to a lesser degree IL17a) transcripts, cytokines not typically associated with Th~2~-like cells, suggests that the CCR4^+^ T~CM~ contains a fraction of cells with a Th~17~-like functionality. Such cells are important in controlling bacterial infections at mucosal surfaces such as the gut and lungs \[[@B53]\]; the measured Th~17~-like functionality correlates well with expression of CD103 mRNA, the protein product of which has been implicated with homing to gut and skin \[[@B54]\].

The recovery kinetics of naïve and memory CD4^+^ T cells on ART have been shown to differ depending on the extent of a patient\'s CD4^+^ T-cell loss at the time of ART initiation \[[@B9]\]. Therefore, the present findings might not apply to all HIV-1^+^ individuals on ART, as we focused our study on severely immuno-compromised patients (\< 200 CD4^+^ T cells/μl). In fact, we found an inverse correlation between CD4^+^ (*P* = 0.0008) or CD8^+^ (*P* = 0.0037) T-cell recovery and the CD4^+^ T-cell count pre-ART, reflecting a greater change in T-cell numbers experienced by those patients starting with a more severe T-cell depletion. Furthermore, individuals with lower pre-ART PVL were found to start with more differentiated CD4^+^ T cells and to exhibit a more rapid drop in late differentiation cells.

However, even though a substantial immune reconstitution occurs in the peripheral blood, it has been demonstrated that the mucosal immune system is more recalcitrant \[[@B55], [@B56]\], with CD4^+^ T cells expressing CCR5 and/or CXCR4 remaining preferentially depleted \[[@B56]\].

Overall we found that even in these very advanced HIV-1^+^ patients the CD4^+^ and CD8^+^ T-cell compartments in peripheral blood slowly revert towards a more "healthy" phenotype, with an overall reduction in the expression of activation markers and molecules associated with inhibition of cellular functions, as well as an upregulation of factors associated with T-cell homeostasis and a more balanced immune system. For the most part, these changes commence early after ART initiation. An exception was an ART-induced increase in the frequency of initially highly activated peripheral CCR4^+^ T~CM~ cells. This reflects a redistribution of these cells from peripheral tissue sites to peripheral blood, caused by a reduction in the viral burden, as highlighted by their expression of mRNA transcripts of the gut- and skin-homing integrin CD103. However, even 1 year post-therapy, the immune system maintains an unusually Th~2~-biased composition, potentially underlying continued immunodeficiency in the presence of higher CD4^+^ T-cell counts.
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SUPPLEMENTARY MATERIALS
=======================

![**Suppression of viral loads and recovery of T-cell counts on ART.** (A) The plasma viral load was determined by measuring HIV-1 RNA at each sampling time-point. The detection threshold was 50 copies/ml (indicated by the broken line), with rare exceptions of 100 or 500 copies/ ml. The CD4/CD8 ratio (B), and number of CD4^+^ T-cells (C) or CD8^+^ T-cells/μl (D) in peripheral blood are shown. Bars illustrate median values, while boxes show the inter-quartile range. Healthy ranges are indicated in orange (generated from 288 healthy donor PBMC processed in the testing laboratory). All time-points were compared to corresponding pre-ART measurements: \* *P* \< 0.01, \*\* *P* \< 0.001, \*\*\* *P* \< 0.0001.](pai-1-260-s001){#FS1}

![**ART-induced change towards less differentiated CD8^+^ T cells.** PBMC were sampled before, as well as after 1, 3, 6, and 12 months of ART. The distribution of differentiation stages (A) and frequency of individual differentiation subsets (B) was investigated in CD8^+^ T cells. T-cell differentiation subsets were defined by expression of CD45RO ("RO"), CCR7 ("R7") and CD27 ("27"). Differentiation indices (DI; medians and interquartile ranges) are indicated next to each pie. The average T-cell differentiation profile as well as the interquartile range of the differentiation indices in healthy donors are shown. (C) Markers of Tcell differentiation. (D) Inhibitory receptors. (E) Markers of activation; GrB-- Granzyme B. (F) Mean fluorescence intensity of CD38. Graphs show interquartile ranges, median bars, as well as individual data points. Orange areas represent the interquartile ranges of corresponding measurements in healthy individuals. All timepoints were compared to corresponding pre-ART measurements: \* *P* \< 0.01, \*\* *P* \< 0.001, \*\*\* *P* \< 0.0001.](pai-1-260-s002){#FS2}

![**Chemokine receptor staining and definition of Th subsets.** Gates for the expression of CCR4, CCR6, CCR10, and CXCR3 were defined within total CD4^+^ T cells. Th subsets were identified by the resulting co-expression pattern, following the gating scheme published in OMIP-017\[[@B57]\].](pai-1-260-s003){#FS3}

![**T-cell subsets sorted for gene expression analysis.** PBMC were stimulated with SEB for 3 hours, before sorting seven CD4^+^ T-cell subsets from SEB-reactive cells as indicated in this gating scheme. After identifying live CD3^+^ cells within singlet, aggregate-negative lymphocytes, non-naive CD4^+^ T cells were selected by excluding CD45RO^−^ CCR7^+^ cells. Within these, T cells expressing TCRVβ12, -Vβ14 or -Vβ17 are known to react to SEB, so FITC-conjugated Abs were used for these three TCR-Vβ chains. Within such SEB-reactive cells, CCR4^+^ and CCR4− cells were selected and individually gated for T~CM~ (CD45RO^+^ CCR7^+^ CD27^+^) or T~CM~^−^ subsets. Further, total SEB-reactive CD4^+^ T cells, as well as stringently gated Th~1~- (CCR4^−^, CCR6^−^, CCR10^−^, CXCR3^+^) and Th~2~-like cells (CCR4^+^ CCR6^−^ CCR10^−^ CXCR3^−^) were also sorted.](pai-1-260-s004){#FS4}

![**CCR4^+^ T~CM~ resemble Th~2~-like cells in respect to their expression of Th~1~ associated genes.** PBMC from healthy donors, as well as cells isolated before or after 1 or 12 months of ART from HIV-1-infected adults were stained with the "sorting" panel ([Supplementary Table 1](#TS1){ref-type="table"}). Subsets of CD4^+^ T cells were sorted as indicated in [Supplementary Figure 4](#FS4){ref-type="fig"} and their gene expression profiles determined by multi-parametric quantitative RT-PCR. (A) Th~1~-associated genes were compared in Th~2-~like, CCR4^+^ T~CM~, and Th~1~-like cells isolated from healthy donors. (B) CCR4^+^ T~CM~ from HIV-1^+^ patients after 1 month of ART were compared to their counterparts from healthy donors in respect to expression of Th~1~-associated genes. Bar graphs show interquartile ranges, median bars, as well as individual data points. Statistically significant differences are indicated: \* *P* \< 0.01, \*\* *P* \< 0.001, \*\*\* *P* \< 0.0001.](pai-1-260-s005){#FS5}

![**Migration marker expression on CD4^+^ T cells.** The expression of migration markers on the cell surface of CD4^+^ T cells was investigated by flow cytometry. (A) Dot plots show the expression of CD103, CCR9, integrin β7, CD49d, and CD11a on CD4^+^ T-cells from two different patients after 1 month of ART. (B) CD103 and CCR9 expression pre-ART and after 1 month of ART compared to healthy donors. (C) CD49d, CD11a, and integrin β7 expression pre-ART and after 1 month of ART compared to healthy donors. Bar graphs show interquartile ranges, median bars, as well as individual data points. Due to the small sample size, no statistical comparison was performed.](pai-1-260-s006){#FS6}

###### 

Reagent panels used for flow cytometric analysis

  Detector[\*](#TFS1-1){ref-type="table-fn"}   Fluorochroe                 Reagents used in panel                                                                                                
  -------------------------------------------- --------------------------- ------------------------ ------------- ------------- ------------- ------------- ------------------------------------ -------------
  *V450*                                       ViViD                       Dead cells               Dead cells    Dead cells    Dead cells    Dead cells    Dead cells                           Dead cells
                                               PacBlu                      CD14 / CD19              CD14 / CD19   CD14 / CD19   CD14 / CD19   CD14 / CD19   CD14 / CD19                          CD14 / CD19
  *V545*                                       QD545                       CD45RO                   CD45RO        CD45RO        CD45RO        CD45RO        CD45RO                               
  *V565*                                       Biotin + SA-QD565 / QD565   CD57                                                                                                                  CD49
  *V585*                                       QD585                       CD8                      CD8           CD8           CD8           CD8           CD8                                  CD8
  *V605*                                       Biotin + SA-QD605 / BV605   PD-1                     PD-1          PD-1          CCR5          PD-1          CCR6                                 CCR6
  *V655*                                       QD655                       CD27                                   CD27          CD27          CD27          CD27                                 CD27
  *V705*                                       QD705                       CD7                      CD57          CD57          CD57                                                             CD11a
  *V800*                                       QD800                       CD4                      CD4           CD4           CD4           CD4                                                CD4
                                                                                                                                                                                                 
  *B515*                                       Ax488 / FITC                IFN-γ                    Ki67          Ki67          Ki67          CCR6          TCR-Vβ^12,\ 14,\ 17^                 CD103
                                                                                                                                                                                                 
  *G560*                                       PE                          TIM-3                    CD38          LAG-3         CD127         CCR10         CCR10                                CCR10
  *G610*                                       Ax594                       TNF                      CCR7                        CD45RA                      TCR-Vβ^1,\ 2,\ 7,\ 13.6,\ 16,\ 22^   CD3
  *G660*                                       PE-Cy5                      CD28                     HLA-DR                      FoxP3         CXCR3         CXCR3                                CXCR3
  *G710*                                       PE-Cy5.5                    CD127                                                              HLA-DR                                             Integrin β7
  *G780*                                       PE-Cy7                      CD31                     CCR5          ICOS          CD25          ICOS          CCR4                                 CCR4
                                                                                                                                                                                                 
  *R660*                                       APC                         IL-2                     Granzyme B    CTLA-4        CCR4          CCR4          CD4                                  CCR9
                                                                                                                                                                                                 
  *R710*                                       Ax680 / Ax700               CCR7                     CD27          CCR7          CCR7          CCR7          CCR7                                 CCR7
  *R780*                                       APC-Cy7                     CD3                      CD3           CD3           CD3           CD3           CD3                                  

ViViD indicates LIVE/DEAD fixable violet dead cell stain; PacBlu, pacific blue; QD, quantum dot; SA, streptavidin; BV, brilliant violet; Ax, alexa; FITC, fluorescein isothiocyanate; PE, R-phycoeryhtrin; Cy, cyanine; APC, allophycocyanin.

\* Detectors are coded by laser colour (V indicates violet; B, blue; G, green; R, red) and mean wavelength measured.

###### 

Genes investigated by quantitative RT-PCR

                                     Gene Symbol    Other names                                                                        Gene Name                                              Assay Catalogue \#
  ---------------------------------- -------------- ---------------------------------------------------------------------------------- ------------------------------------------------------ --------------------
  *Cytokines*                        CSF2           GM-CSF                                                                             (granulocyte-macrophage) colony stimulating factor 2   Hs00929873_m1
  IFNg                                              interferon gamma                                                                   Hs00174143_m1                                          
  IL2                                               interleukin 2                                                                      Hs00174114_m1                                          
  IL3                                               interleukin 3 (colony-stimulating factor for multiple cell types)                  Hs99999081_m1                                          
  IL4                                               interleukin 4                                                                      Hs00929862_m1                                          
  IL5                                               interleukin 5 (colony-stimulating factor for eosinophils)                          Hs99999031_m1                                          
  IL6                                               interleukin 6 (interferon, beta 2)                                                 Hs00985639_m1                                          
  IL8                                               interleukin 8                                                                      Hs99999034_m1                                          
  IL9                                HP40, P40      interleukin 9                                                                      Hs00914237_m1                                          
  IL10                                              interleukin 10                                                                     Hs00961622_m1                                          
  IL13                                              interleukin 13                                                                     Hs99999038_m1                                          
  IL16                                              interleukin 16 (lymphocyte chemo-attractant factor)                                Hs00189606_m1                                          
  IL17a                                             interleukin 17A                                                                    Hs00174383_m1                                          
  IL21                                              interleukin 21                                                                     Hs00222327_m1                                          
  IL22                                              interleukin 22                                                                     Hs00220924_m1                                          
  IL26                                              interleukin 26                                                                     Hs00218189_m1                                          
  LTA                                TNFb           lymphotoxin alpha (TNF superfamily, member 1)                                      Hs00236874_m1                                          
  LTB                                TNFc           lymphotoxin beta (TNF superfamily, member 3)                                       Hs00242739_m1                                          
  TGFB1                                             transforming growth factor, beta 1                                                 Hs00998133_m1                                          
  TGFB2                                             transforming growth factor, beta 2                                                 Hs01548875_m1                                          
  TNF                                TNFa           tumor necrosis factor                                                              Hs00174128 m1                                          
  *Cytokine receptors*               IL2Ra          CD25                                                                               interleukin 2 receptor, alpha                          Hs00907778_m1
  IL2Rb                              CD122          interleukin 2 receptor, beta                                                       Hs01081697_m1                                          
  IL3RA                              CD123          interleukin 3 receptor, alpha (low affinity)                                       Hs00608141_m1                                          
  IL4Ra                              CD124          interleukin 4 receptor                                                             Hs00166237_m1                                          
  IL5Ra                              CD125          interleukin 5 receptor, alpha                                                      Hs01064360_m1                                          
  IL6R                               CD126          interleukin 6 receptor                                                             Hs01075667_m1                                          
  IL6ST                              gp130          interleukin 6 signal transducer (oncostatin M receptor)                            Hs00174360_m1                                          
  IL7R                               CD127          interleukin 7 receptor                                                             Hs00233682_m1                                          
  IL10Ra                             CD210          interleukin 10 receptor, alpha                                                     Hs00155485_m1                                          
  IL12RbI                            CD212          interleukin 12 receptor, beta 1                                                    Hs00538167_m1                                          
  IL12RbII                                          interleukin 12 receptor, beta 2                                                    Hs01548202_m1                                          
  IL18Ra                             IL-18R1        interleukin 18 receptor 1                                                          Hs00977691_m1                                          
  IL21R                                             interleukin 21 receptor                                                            Hs00222310_m1                                          
  TGFBR1                                            transforming growth factor, beta receptor 1                                        Hs00610318_m1                                          
  TGFBR3                             BGCAN          transforming growth factor, beta receptor 3                                        Hs01114253 m1                                          
  *Migration-associated receptors*   CCR1           CD191                                                                              C-C motif chemokine receptor 1                         Hs00174298_m1
  CCR2                               CD192          C-C motif chemokine receptor 2                                                     Hs00356601_m1                                          
  CCR3                               CD193          C-C motif chemokine receptor 3                                                     Hs00266213_s1                                          
  CCR4                               CD194          C-C motif chemokine receptor 4                                                     Hs99999919_m1                                          
  CCR5                               CD195          C-C motif chemokine receptor 5                                                     Hs00152917_m1                                          
  CCR6                               CD196          C-C motif chemokine receptor 6                                                     Hs00171121_m1                                          
  CCR7                               CD197          C-C motif chemokine receptor 7                                                     Hs99999080_m1                                          
  CCR8                                              C-C motif chemokine receptor 8                                                     Hs00174764_m1                                          
  CCR10                                             C-C motif chemokine receptor 10                                                    Hs00706455_s1                                          
  CD103                              ITGAE          integrin, alpha E (human mucosal lymphocyte antigen 1; alpha polypeptide)          Hs00559580_m1                                          
  CXCR1                              IL-8R1         C-X-C motif chemokine receptor 1                                                   Hs00174146_m1                                          
  CXCR2                              IL-8R2         C-X-C motif chemokine receptor 2                                                   Hs01011557_m1                                          
  CXCR3                              CD183b, MIGR   C-X-C motif chemokine receptor 3                                                   Hs00171041_m1                                          
  CXCR4                                             C-X-C motif chemokine receptor 4                                                   Hs00976734_m1                                          
  CXCR5                                             C-X-C motif chemokine receptor 5                                                   Hs00173527_m1                                          
  CXCR6                                             C-X-C motif chemokine receptor 6                                                   Hs00174843_m1                                          
  GPR44                              CRTH2, CD294   G protein-coupled receptor 44                                                      Hs00173717 m1                                          
  *Prolif.*                          MKI67          Ki67                                                                               antigen identified by monoclonal antibody Ki67         Hs01032443_m1
  PCNA                                              proliferating cell nuclear antigen                                                 Hs00696862_m1                                          
  *Chemokines*                       CCL2           MCP1                                                                               C-C motif chemokine ligand 2                           Hs00234140_m1
  CCL3                               MIP-1α         C-C motif chemokine ligand 3                                                       Hs00234142_m1                                          
  CCL4                               MIP-1β         C-C motif chemokine ligand 4                                                       Hs01031494_m1                                          
  CCL5                               RANTES         C-C motif chemokine ligand 5                                                       Hs00174575_m1                                          
  CXCL9                              MIG            C-X-C motif chemokine ligand 9                                                     Hs00171065_m1                                          
  CXCL10                                            C-X-C motif chemokine ligand 10                                                    Hs00171042_m1                                          
  CXCL11                             I-TAC          C-X-C motif chemokine ligand 11                                                    Hs00171138_m1                                          
  CXCL13                             BLC, BCA-1     C-X-C motif chemokine ligand 13                                                    Hs00757930 m1                                          
  *Cytolysis*                        GNLY                                                                                              granulysin                                             Hs00246266_m1
  GZMA                               CTLA3          granzyme A (granzyme 1; cytotoxic T-lymphocyte associated serine esterase 3)       Hs00989184_m1                                          
  GZMB                               CTLA1          granzyme B (granzyme 2; cytotoxic T-lymphocyte associated serine esterase 1)       Rh02621701_m1                                          
  GZMH                               CTSG           granzyme H (cathepsin Glike 2; protein hCCPX)                                      Hs00277212_m1                                          
  GZMK                               TRYP2          granzyme K (granzyme 3; tryptase II)                                               Hs00157878_m1                                          
  GZMM                               MET1           granzyme M (lymphocyte metase 1)                                                   Hs00193417_m1                                          
  PRF1                               Perforin       perforin 1 (pore forming protein)                                                  Hs00169473 m1                                          
  *Transcription factors*            ARNT                                                                                              aryl hydrocarbon receptor nuclear translocator         Hs00231048_m1
  EOMES                              TBR2           eomesodermin                                                                       Hs00172872_m1                                          
  FOXP3                                             forkhead box P3                                                                    Hs00203958_m1                                          
  GATA3                                             GATA binding protein 3                                                             Hs00231122_m1                                          
  RORC                               RORgT          RAR-related orphan receptor C                                                      Hs01076112_m1                                          
  SOCS-1                                            suppressor of cytokine signaling 1                                                 Hs00705164_s1                                          
  STAT1                                             signal transducer and activator of transcription 1                                 Rh02899274_m1                                          
  STAT3                                             signal transducer and activator of transcription 3 (acute-phase response factor)   Hs01047580_m1                                          
  STAT4                                             signal transducer and activator of transcription 4                                 Rh02896026_m1                                          
  STAT5A                                            signal transducer and activator of transcription 5A                                Rh02844611_m1                                          
  STAT6                                             signal transducer and activator of transcription 6                                 Hs00598625_m1                                          
  TBX21                              T-bet          Tbox 21                                                                            Hs00894392 m1                                          
  *Activation*                       CD38                                                                                              CD38 molecule                                          Hs01120071_m1
  CTLA4                                             cytotoxic T-lymphocyte associated protein 4                                        Hs03044418_m1                                          
  HLADRA                                            major histocompatibility complex, class II, DR alpha                               Hs00219575_m1                                          
  HAVCR1                             TIM-1          hepatitis A virus cellular receptor 1                                              Rh02863844_m1                                          
  HAVCR2                             TIM-3          hepatitis A virus cellular receptor 2                                              Hs00958623_m1                                          
  LAG3                               CD223          lymphocyte activation gene 3                                                       Hs00158563_m1                                          
  PD1                                PDCD1          programmed cell death 1                                                            Hs01550088 m1                                          
  *Costimulation*                    ICOS                                                                                              inducible T-cell costimulator                          Hs00359999_m1
  TNFRSF1                            RANK           tumor necrosis factor receptor superfamily, member 11a, NFKB activator             Hs00187192_m1                                          
  TNFRSF4                            Ox40           tumor necrosis factor receptor superfamily, member 4                               Hs00533968_m1                                          
  TNFRSF9                            CD137, 4-1BB   tumor necrosis factor receptor superfamily, member 9                               Hs00155512_m1                                          
  TNFSF10                            TRAIL          tumor necrosis factor (ligand) superfamily, member 10                              Hs00921974_m1                                          
  TNFSF13B                           BAFF           tumor necrosis factor (ligand) superfamily, member 13b                             Hs00198106_m1                                          
  TNFSF14                            LIGHT          tumor necrosis factor (ligand) superfamily, member 14                              Hs00187011 m1                                          
